Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics

Neurology

Volumn 74, Issue 1 SUPPL., 2010, Pages

  Leist, Thomas P ^a,b   Marks, Steven ^a,c  

^a Thomas Jefferson University ^*  (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Expert Medical Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE;

AXONAL INJURY; BRAIN ATROPHY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 74149095085     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c98011     Document Type: Article

References (49)

1. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68(suppl 3):S72-S82.
2. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005;15(suppl 4):10S-21S. (Pubitemid 43010528)
3. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia. MS/MRI Analysis Group. Neurology 1995;45:1277-1285.
4. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869.
5. Wolansky L, Cook S, Skurnick J, et al. Betaseron [IFNB-1b] vs. Copaxone [glatiramer acetate] in MS with tripledose gadolinium and. 3 T MRI endpoints (BECOME): announcement of final primary study outcomes. Mult Scler 2007;12(suppl2): S58.
6. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
7. Markovic-Plese S, McFarland HF. Immunopathogenesis of the multiple sclerosis lesion. Curr Neruol Neurosci Rep 2001;1:257-262.
8. McDonald WI, Compston DAS, Edan G, et al. Recommended diagnostic criteria for MS. Ann Neurol 2001;50: 121-127.
9. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268-275.
10. Filippi M, Rovaris M, Comi G. Introduction. In: Filippi M, Comi G, editors. New Frontiers in Multiple Sclerosis. Milan, Italy: Springer-Verlag; 2003:1-3.
11. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121: 495-503.
12. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817.
13. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164. (Pubitemid 34438881)
14. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47-53. (Pubitemid 34693742)
15. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6:677-686. (Pubitemid 47064439)
16. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249. (Pubitemid 44563835)
17. Swanton JK, Fernando KT, Dalton CM, et al. Brain lesion number and spinal cord lesions in clinically isolated syndrome patients and the risk for clinically definite multiple sclerosis. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic; October 12, 2007:P269.
18. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict longterm disability in patients with initial findings suggestive of multiple sclerosis. Ann Neurol 2004;61:217-221. (Pubitemid 38197554)
19. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
20. Comi G, Filippi M, Barkhof F, et al; Early Treatment of Multiple Sclerosis Study Group Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
21. Comi G, Filippi M. Treatment with glatiramer acetate delays conversion to clinically definite MS in patients with clinically isolated syndromes. Presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago, IL; April 12-19, 2008:LBS. 003.
22. 22. Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N. A Wallerian degeneration pattern in patients at risk for MS. Neurology 2000;54:1155-1160. (Pubitemid 30151861)
23. Fotcnos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008;65:113-120.
24. Khan O, MacKenzie M, Bao F, et al. Effect of Disease-Modifying Therapies (DMT) on brain atrophy in early and mildly affected. RRMS over a long-term period: results of a five-year imaging study. Neurology 2008;70(suppl 1): A472.
25. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420. (Pubitemid 35285996)
26. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-582. (Pubitemid 41387703)
27. Stangel M. Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opin Investig Drugs 2004; 13: 331-347. (Pubitemid 38489524)
28. Jones CK, Riddehough A, Li DKB, Zhao GJ, Paty DW. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. Neurology 2001;56:A379.
29. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704. (Pubitemid 29530342)
30. Mikol DD, Barkhof F, Chang P, et al; REGARD study group. Comparison of subcutaneous interferon beta-1a. with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-914.
31. O'Connor P, Filippi M, Amason B, et al; BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 nig glatiramer acetate in relapsingremitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897.
32. Barkhof F, Filippi M. Can MR be a predictor of long-term clinical outcome for MS? Int MS J 1995;2:4-9.
33. van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE (T1-weighted.) spin-echo images. Neurology 1995;45:1684-1690.
34. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476. (Pubitemid 26422538)
35. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-754. (Pubitemid 29518136)
36. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-1789. (Pubitemid 36917337)
37. Filippi M, Rovaris M, Rocca MA, et al; Eurpoean/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.
38. Brex PA, Molyneux PD, Smiddy P, et al; European Study Group on Interferon beta-1b in Secondary Progressive MS. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57:2185-2190.
39. Larsson HB, Christiansen P, Jensen M, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1991;22:23-31.
40. Matthews PM, Francs G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991; 41:1251-1256.
41. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11:646-651. (Pubitemid 41685134)
42. Khan O, Shen Y, Bao F, et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008;18:314-319.
43. Narayanan S, Caramanos Z, Arnold D. The effect of glatiramer acetate on axonal integrity in multiple sclerosis. Mult Scler 2004:10(suppl 2):S256.
44. Sarchielli P, Prcsciutti O, Tarducci R, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998;64:204-212. (Pubitemid 28159802)
45. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-986. (Pubitemid 36124725)
46. Parry A, Corkill R, Blamire AM, et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003;250:171-178. (Pubitemid 36223091)
47. Cree B, Ratiney H, Owen M, Evangelista A, Oh J, Pelletier D. Magnetic resonance spectroscopy effects of natalizumab: single center results from the SENTINEL study. Neurology 2007;68(suppl 1):A54.
48. Richert N, Bagnato F, Howard T, et al. Whole brain magnetic transfer analysis of relapsing-remitting multiple sclerosis patients treated with IFNB-1b or glatiramer acetate. Mult Scler 2003;9(suppl 1):S64. Abstract P273.
49. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility- weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19-30.